| 1 | Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC | OncoImmunology | 2016 | 694 |
| 2 | Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death | OncoImmunology | 2014 | 536 |
| 3 | Role of IL-2 in cancer immunotherapy | OncoImmunology | 2016 | 457 |
| 4 | EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer | OncoImmunology | 2017 | 390 |
| 5 | IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan | OncoImmunology | 2012 | 377 |
| 6 | CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+T cells | OncoImmunology | 2013 | 352 |
| 7 | Targeting PD-1/PD-L1 interactions for cancer immunotherapy | OncoImmunology | 2012 | 345 |
| 8 | PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy? | OncoImmunology | 2018 | 337 |
| 9 | Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer | OncoImmunology | 2017 | 334 |
| 10 | Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands | OncoImmunology | 2012 | 319 |
| 11 | First oncolytic virus approved for melanoma immunotherapy | OncoImmunology | 2016 | 319 |
| 12 | Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer | OncoImmunology | 2018 | 313 |
| 13 | The prognostic role of tumor infiltrating T-lymphocytes in squamous cell carcinoma of the head and neck: A systematic review and meta-analysis | OncoImmunology | 2017 | 305 |
| 14 | TIM3+FOXP3+regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer | OncoImmunology | 2013 | 300 |
| 15 | Glioblastoma stem cell-derived exosomes induce M2 macrophages and PD-L1 expression on human monocytes | OncoImmunology | 2018 | 298 |
| 16 | Exogenous lipid uptake induces metabolic and functional reprogramming of tumor-associated myeloid-derived suppressor cells | OncoImmunology | 2017 | 294 |
| 17 | CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial | OncoImmunology | 2018 | 294 |
| 18 | Hypoxic tumor-derived microvesicles negatively regulate NK cell function by a mechanism involving TGF-β and miR23a transfer | OncoImmunology | 2016 | 291 |
| 19 | Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases | OncoImmunology | 2016 | 282 |
| 20 | Interaction of tumor-associated macrophages and cancer chemotherapy | OncoImmunology | 2019 | 277 |
| 21 | Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer | OncoImmunology | 2017 | 275 |
| 22 | TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM | OncoImmunology | 0 | 269 |
| 23 | Targeting CD73 in the tumor microenvironment with MEDI9447 | OncoImmunology | 2016 | 264 |
| 24 | CD39/CD73 upregulation on myeloid-derived suppressor cells via TGF-β-mTOR-HIF-1 signaling in patients with non-small cell lung cancer | OncoImmunology | 2017 | 264 |
| 25 | Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines | OncoImmunology | 2017 | 256 |
| 26 | A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes | OncoImmunology | 2013 | 253 |
| 27 | Extracellular vesicle-mediated transfer of functional RNA in the tumor microenvironment | OncoImmunology | 2015 | 250 |
| 28 | Eosinophils: The unsung heroes in cancer? | OncoImmunology | 2018 | 248 |
| 29 | The IRF family of transcription factors | OncoImmunology | 2012 | 246 |
| 30 | High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer | OncoImmunology | 2017 | 242 |
| 31 | Prognostic value of tumor-infiltrating lymphocytes in melanoma: a systematic review and meta-analysis | OncoImmunology | 2019 | 242 |
| 32 | Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics | OncoImmunology | 2017 | 237 |
| 33 | Tumor mutational burden is a determinant of immune-mediated survival in breast cancer | OncoImmunology | 2018 | 235 |
| 34 | Tumor-associated neutrophils display a distinct N1 profile following TGFβ modulation: A transcriptomics analysis of pro- vs. antitumor TANs | OncoImmunology | 2016 | 232 |
| 35 | Insufficient autophagy promotes bronchial epithelial cell senescence in chronic obstructive pulmonary disease | OncoImmunology | 2012 | 226 |
| 36 | Priming of neutrophils toward NETosis promotes tumor growth | OncoImmunology | 2016 | 226 |
| 37 | Trial watch | OncoImmunology | 2012 | 223 |
| 38 | The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200 | OncoImmunology | 2017 | 223 |
| 39 | Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy | OncoImmunology | 2012 | 216 |
| 40 | Warburg metabolism in tumor-conditioned macrophages promotes metastasis in human pancreatic ductal adenocarcinoma | OncoImmunology | 2016 | 216 |
| 41 | Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer | OncoImmunology | 2017 | 215 |
| 42 | Cytokine patterns in cancer patients: A review of the correlation between interleukin 6 and prognosis | OncoImmunology | 2016 | 214 |
| 43 | The exosomes in tumor immunity | OncoImmunology | 2015 | 210 |
| 44 | Trial Watch: Toll-like receptor agonists in cancer immunotherapy | OncoImmunology | 2018 | 206 |
| 45 | Immunological metagene signatures derived from immunogenic cancer cell death associate with improved survival of patients with lung, breast or ovarian malignancies: A large-scale meta-analysis | OncoImmunology | 2016 | 205 |
| 46 | Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma | OncoImmunology | 2016 | 204 |
| 47 | A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab | OncoImmunology | 2015 | 203 |
| 48 | The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells | OncoImmunology | 2016 | 203 |
| 49 | Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma | OncoImmunology | 2016 | 201 |
| 50 | Tumor infiltration by Tbet+ effector T cells and CD20+ B cells is associated with survival in gastric cancer patients | OncoImmunology | 2016 | 195 |
